Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG)

European Journal of Haematology

Volumn 64, Issue 3, 2000, Pages 182-187

  Tedeschi, A ^a   Montillo, M ^a   Ferrara, F ^b   Nosari, A ^a   Mele, G ^b   Copia, C ^b   Leoni, P ^c   Morra, E ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c Ospedale Niguarda Ca' Granda ^*

Author keywords

Biastic phase CML; Cytosine arabinoside; Fludarabine; G CSF

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERFERON;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; LEUKEMIA REMISSION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; BONE MARROW TRANSPLANTATION; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; REMISSION INDUCTION; VIDARABINE;

EID: 0034098923     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.90066.x     Document Type: Article

References (47)

1. 1. CORTES EJ, TALPAZ M, KANTARJIAN H. Chronic myelogenous leukemia: a review. Am J Med 1996;100:555-570.
2. 2. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-825.
3. 3. KANTARJIAN HM, et al. Prolonged survival following achievement of cytogenetic response with alpha interferon therapy in chronic myelogenous leukemia. Ann Intern Med 1995;122:254-261.
4. 4. ROBERTSON MJ, TANTRAVAHI R, GRIFFIN JD, CANNELLOS GP, CANNISTRA SS. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol 1993;43:95-102.
5. 5. KLOKE O, et al. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukemia. Br J Haematol 1993;83:399-403.
6. 6. OHNISHI K, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906-916.
7. 7. GUILHOT F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-229.
8. 8. KANTARJIAN H, et al. Chronic myelogenous leukemia in blastic crisis: analysis of 242 patients. Am J Med 1987;83: 445-454.
9. 9. COLEMAN M, et al. Combination chemotherapy for terminal phase chronic granulocytic leukemia: Cancer and Leukemia Group B studies. Blood 1980;55:29-36.
10. 10. DUTCHER JP, et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia 1992;6:770-775.
11. 11. DERDERIAN PM, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993;94:69-74.
12. 12. WALTERS RS, et al. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer 1987;60:1708-1712.
13. 13. MARKS SM, BALTIMORE D, MCCAFFREY R. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia. N Engl J Med 1978;293:812-814.
14. 14. JANNOSSY G, et al. Relation of "lymphoid" phenotype as response to chemotherapy incorporating vincristine-prednisone in the acute phase of Ph+ positive leukemia. Cancer 1979;43:426-434.
15. 15. TANAKA M, et al. Terminal deoxynucleotidyl transferase in the blastic phase of chronic myelogenous leukemia: an indicator of response to vincristine and prednisone therapy. Am J Hematol 1980;9:278-293.
16. 16. JACOBONI SJ, et al. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 1986;4:1079-1088.
17. 17. HERZIG RH, WOLFF SN, LAZZARUS HM, PHILLIPS GL, KARANES C, HERZIG GP. High dose cytosine arabinoside therapy for refractory leukemia. Blood 1984;63:694-700.
18. 18. ERNST TJ, et al. Treatment of the blastic phase of chronic myelogenous leukemia with high dose cytosine arabinoside. Am J Clin Oncol 1988;11:623-626.
19. 19. KANTARJIAN HM, et al. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 1988;62:672-676.
20. 20. KANTARJIAN HM, et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phase with daunorubicin, high-dose cytarabine and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1992;10:398-405.
21. 21. IWAO N, et al. Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: a pilot study. Leuk Res 1995;19:899-903.
22. 22. ESTEY E, et al. Treatment of poor-prognosis newly diagnosed AML or MDS with G-CSF prior to, during and following fludarabine and Ara-C. Blood 1991;78(suppl 1): 439a.
23. 23. ESTEY E, et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymph 1993;9:343-347.
24. 24. MONTILLO M, et al. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998;58:105-109.
25. 25. MONTILLO M, TEDESCHI A, CENTURIONI R, LEONI P. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony stimulating factor. Leuk Lymp 1997;25: 579-582.
26. 26. VISANI G, et al. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen exspression. Eur J Haematol 1996;56: 308-312.
27. 27. GANDHI V, KEMENA A, KEATING MJ. Fludarabine potentiates arabinosyl-cytosina metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 1992;52:897-903.
28. 28. GANDHI V, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116-123.
29. 29. JOHNSON PRE, LIU YIN JA. The role of granulocyte-and granulocyte-macrophage-colony-stimulating factors in the treatment of acute myeloid leukaemia. Br J Haematol 1997; 97:1-8.
30. 30. TAFURI A, ANDREEFF M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990;4: 826-834.
31. 31. ROWE JM, LIESVELD JL. Hematopoietic growth factors in acute leukemia. Leukemia 1997;11:328-341.
32. 32. TOSI P, VISANI G, OTTAVIANI E, MANFROI S, ZINZANI PL, TURA S. Fludarabine+Ara-C+G-CSF: cytotoxic effect and induction of apoptosis on fresh acute leukemia cells. Leukemia 1994;8:2076-2082.
33. 33. ZINZANI PL, et al. Apoptosis induction with fludarabine in freshly isolated chronic myeloid leukemia cells. Hematologica 1994;79:127-131.
34. 34. VISANI G, et al. FLAG (fludarabine+cytosine arabinoside+ G-CSF) induces complete remission in acute-phase chronic myeloid leukemia: a case report. Br J Haematol 1994;86:394-396.
35. 35. MARTINELLI G, et al. FLANG (fludarabine+cytosine arabinoside+novantrone+G-CSF) induces partial remission in lymphoid blast transformation of Ph+ chronic myelogenous leukaemia. Leuk Lymphoma 1996;22: 173-176.
36. 36. MILLER AB, HOOGSTRATEN B, STAQUET M, WINKLER A. Reporting results of cancer treatment. Cancer 1981;47: 207-214.
37. 37. BRIONES J, PEREIRA A, ALCORTA I. Transfusion associated graft-versus-host disease (TA-GVHD) in fludarabine treated patients: is it time to irradiate blood component? Br J Haematol 1996;93:739-741.
38. 38. PREISLER HD. Treatment failures in AML. Blood Cells 1982;8:585-602.
39. 39. CENTURIONI R, et al. Intensive polychemotherapy experience in chronic myeloid leukemia. Haematologica 1989;74: 491-493.
40. 40. GOLDMAN JM, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. Ann Intern Med 1986;104:155-163.
41. 41. HANSEN JA, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-968.
42. 42. RUDIGER H. A chance of cure for every patient with chronic myeloid leukemia? N Engl J Med 1998;338:980-981.
43. 43. WINTON EF, MILLER D, VOGLER WR. Intensive chemotherapy with daunorubicin, 5 azacytidine, 6-thioguanine and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia. Cancer Treat Rep 1981;64: 389-392.
44. 44. CORTES J, et al. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia 1997;11:788-791.
45. 45. MONTEFUSCO E, et al. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia. Ann Oncol 1997;8:175-179.
46. 46. DUTCHER JP, LEE S, PAIETTA E, BENNETT JM, STEWART JA, WIERNIK PH. Carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992. Leukemia 1998;12:1037-1040.
47. 47. CHESON BD, VENA DA, FOSS FM, SORENSEN JM. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994; 12:2216-2228.